152 filings
Page 3 of 8
F-1/A
up0hff
31 Aug 23
Registration statement (foreign) (amended)
4:16pm
CORRESP
6pselk9jkeqjb
31 Aug 23
Correspondence with SEC
12:00am
6-K
q1c4w
16 Aug 23
NeuroSense Announces Second Quarter 2023 Financial Results and Provides Business Update
4:01pm
F-1/A
q5w jf19h28mnd
14 Aug 23
Registration statement (foreign) (amended)
4:16pm
CORRESP
527oy
14 Aug 23
Correspondence with SEC
12:00am
UPLOAD
h1205xh4ee2qvo80y0
1 Aug 23
Letter from SEC
12:00am
F-1
gk2morfzq947v
21 Jul 23
Registration statement (foreign)
4:27pm
6-K
707caebsl d73v
6 Jul 23
NeuroSense CEO Provides Q2 2023 Update
8:30am
D
iap o9pgwlr
5 Jul 23
Exempt offering of security
2:09pm
6-K
zp0a0zkei2m5tpd gol
23 Jun 23
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement
4:06pm
424B5
bme2jtd 8u6tktgf5fmr
23 Jun 23
Prospectus supplement for primary offering
4:05pm
424B5
hkee 6biwld
22 Jun 23
Prospectus supplement for primary offering
6:12am
6-K
k4g6o2 802opmcdp0c
13 Jun 23
Report of Foreign Private Issuer
8:30am
6-K
rk73wv57cpvg0
8 Jun 23
Report of Foreign Private Issuer
9:16am
6-K
pqj6rycl8 bkf
1 Jun 23
Report of Foreign Private Issuer
8:50am
6-K
qhgwppvs6y
31 May 23
Report of Foreign Private Issuer
4:01pm
6-K
tb9u7jj
25 May 23
Report of Foreign Private Issuer
9:00am
6-K
5oejmzlgieb
15 May 23
NeuroSense Completes Enrollment in Phase 2b ALS Clinical Trial
9:09am
6-K
jd1mhb73 74881y
2 May 23
Report of Foreign Private Issuer
4:05pm
6-K
up89yh18 sm
2 May 23
NeuroSense Therapeutics Reports Positive Preliminary Results in Parkinson’s Biomarker Study
10:46am